Erdheim-Chester Disease

J.C. Benson; R. Vaubel; B.A. Ebne; I.T. Mark; M. Peris Celda; C.C. Hook; W.O. Tobin; C. Giannini

doi:10.3174/ajnr.A7832

Abstract

SUMMARY: Erdheim-Chester disease is a rare non-Langerhans cell histiocytosis. The disease is widely variable in its severity, ranging from incidental findings in asymptomatic patients to a fatal multisystem illness. CNS involvement occurs in up to one-half of patients, most often leading to diabetes insipidus and cerebellar dysfunction. Imaging findings in neurologic Erdheim-Chester disease are often nonspecific, and the disease is commonly mistaken for close mimickers. Nevertheless, there are many imaging manifestations of Erdheim-Chester disease that are highly suggestive of the disease, which an astute radiologist could use to accurately indicate this diagnosis. This article discusses the imaging appearance, histologic features, clinical manifestations, and management of Erdheim-Chester disease.

ABBREVIATIONS:

CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids
ECD: Erdheim-Chester disease
LCH: Langerhans cell histiocytosis
MAPK: mitogen-activated protein kinase
MEK: mitogen-activated ERK kinase
RDD: Rosai-Dorfman disease

A 24-year-old previously healthy man presented to an outside institution with a subacute history of neurologic symptoms that began 2 weeks after a coronavirus disease 2019 (COVID-19) immunization booster, including headaches, slurred speech, and imbalance. MR imaging showed multifocal enhancing abnormalities of his brainstem and spinal cord. CSF analysis detected no oligoclonal bands and 2 white blood cells/high power field (protein = 99 mg/dL, glucose = 67 mg/dL). The patient was given IV methylprednisolone and an oral prednisone taper after testing had ruled out an infection. His symptoms subsequently improved but did not resolve. On examination at our institution, he had an ataxic dysarthria, gait ataxia, and bilateral leg spasticity. After a water-deprivation test, blood and urine analysis revealed elevated prolactin and central diabetes insipidus, with plasma hyperosmolality (302 mOsm/kg) and low urine osmolality (144 mOsm/kg) in the setting of polyuria. Repeat CSF analysis findings were unremarkable except for 8 white cells/high power field (protein = 136 mg/dL and glucose = 49 mg/dL). The patient was then sent for additional MR imaging of his neuraxis.

Imaging

Initial CT images obtained at the outside institution demonstrated patchy areas of hypoattenuation centered around the dentate nuclei of both cerebellar hemispheres. MR imaging demonstrated extensive multifocal T2-hyperintense signal abnormalities and regions of poorly marginated patchy enhancement. These were predominantly located in an almost symmetric distribution in the midbrain, dentate nuclei, and cerebellar peduncles (Fig 1). None of the abnormalities demonstrated restricted diffusion. There was a mild local mass effect associated with these findings, without obstructive hydrocephalus. Lesser involvement was observed in the periatrial white matter and optic chiasm. The pituitary infundibulum was thickened and demonstrated prominent enhancement. In the spine, similar T2-hyperintense enhancing abnormalities were seen throughout the cervical and thoracic cord (Fig 2). A whole-body PET was performed to evaluate a systemic disorder, which revealed FDG uptake in the distal femoral diaphysis with increased intramedullary density on the corresponding CT images.

FIG 1.

MR images of the posterior fossa demonstrate multifocal abnormalities involving both cerebellar hemispheres, particularly located around the dentate nuclei. These regions are bright on T2 and FLAIR (arrows in A and B), lack restricted diffusion (C), are hypointense on T1 (arrows in D), and demonstrate patchy enhancement on postcontrast T1 fat-saturated images (E). Similar patchy enhancement is also noted in the midbrain (dashed oval on F).

FIG 2.

MR imaging of the cervical (A) and thoracic (B and C) spine demonstrates numerous patchy areas of enhancement along the cervicothoracic cord (A and B). Corresponding fat-saturated STIR images of the thoracic spine demonstrate multifocal T2 hyperintensities in these regions (C).

During the patient’s numerous imaging examinations, a long list of potential diagnoses was brought forth. The imaging appearance and temporal relation with the patient’s immunization booster raised the question of a viral encephalomyelitis. Neurosarcoidosis, tuberculous, and primary CNS lymphoma were also considered as possibilities, given the multifocal signal abnormalities. Demyelinating disease was thought unlikely, given the distribution of findings and lumbar puncture results. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) was similarly considered unlikely, given the lack of a complete radiologic response to steroids and the size of the enhancing lesions.

Operative Report

The decision was made to perform a left cerebellar stereotactic needle biopsy, because it was deemed the safest area with the highest yield for diagnosis. An initial biopsy attempt was aborted because brisk bleeding was encountered after early tissue sampling, pathology was nondiagnostic, and the patient’s postoperative course was uneventful. The second procedure was planned a few weeks later using a slightly different trajectory while targeting the same region. The patient was anesthetized and positioned lateral with the head fixed in a Mayfield head holder. By means of neuronavigation, a linear incision was performed over the planned entry point, and a new burr-hole was obtained. After a small durotomy and corticotomy were performed, a stereotactic biopsy needle was carefully advanced to the target under neuronavigation guidance. Several cylinders of tissue were obtained for biopsy without incident. Frozen pathology was consistent with lesional tissue. The patient awoke at his neurologic baseline and had an uneventful postoperative course.

Pathology

Histopathologic diagnosis in this case was very challenging. The initial cerebellar biopsy was nondiagnostic, showing only the cerebellar cortex with nonspecific Purkinje cell loss and Bergmann gliosis. The subsequent biopsy demonstrated white matter with mild, diffuse hypercellularity (Fig 3). The increased cellularity was due predominantly to foamy macrophages with small nuclei, present in a perivascular distribution and infiltrating the white matter (highlighted by CD68 immunostain). Although cytologically bland, by immunohistochemistry, the foamy macrophages showed apparent expression of BRAF p.V600E, a finding that was confirmed by digital droplet polymerase chain reaction. There was no acute inflammation, multinucleated giant cells, or eosinophils. Stains to evaluate a viral etiology or glial neoplasm were negative. Overall, in the context of the clinical history and imaging, the findings were most consistent with Erdheim-Chester disease (ECD). Subsequently, the patient underwent biopsy of a skin lesion on his back. Histopathologic findings of that biopsy were much more impressive, with numerous, large BRAF-mutant foamy histocytes and Touton giant cells, findings characteristic of ECD.

FIG 3.

H&E-stained sections of the cerebellar biopsy (A) demonstrate mildly hypercellular white matter with increased foamy macrophages (black arrows), highlighted by CD68 immunostain (B). The macrophages were cytologically bland but show expression of BRAF p.V600E (C), supporting the presence of a histiocytic neoplasm. A subsequent skin biopsy (D) shows more characteristic features of ECD, including large, foamy macrophages (black arrows) and Touton giant cells (red arrows), which were positive for BRAF p.V600E (E). Original magnification ×200 for all images.

DISCUSSION

ECD is a rare non-Langerhans cell histiocytosis, in which tissues are infiltrated by lipid-laden histiocytes.¹ Affected patients are typically between their fifth and seventh decades of life, and the disease has a predilection for men.² ECD can affect any tissue, and the clinical manifestations are extremely heterogeneous.³ Because bone, particularly the appendicular skeleton, is almost universally involved, patients may present with nonspecific bone pain; however, bony disease is frequently asymptomatic.⁴ The severity of ECD ranges from incidental discovery in asymptomatic patients to smoldering focal involvement and multisystem fatal forms.⁵

CNS involvement occurs in up to 50% of patients with ECD.^6,7 The most commonly involved sites are the brain parenchyma, hypothalamic pituitary axis, and meninges.⁸ Clinical symptoms of neurologic ECD are dependent on the sites of involvement. Diabetes insipidus is the most frequent manifestation; seizures, pontocerebellar dysfunction, and other neuroendocrine abnormalities including panhypopituitarism are also common.⁹ In rare cases, ECD can present as a neuropsychiatric disorder or cognitive decline.¹⁰

The imaging appearance of neurologic ECD is dependent on distribution and extent. Intracranially, ECD often involves the posterior fossa. The most common findings are multifocal FLAIR hyperintensities of the dentate nuclei and brainstem, demonstrating variable enhancement, with or without atrophy of the affected structures.¹¹ Supratentorial structures, too, can be involved, though less often. In other patients, dural-based enhancing masses are seen, sometimes with a stellate appearance.^1,12 Sella imaging may demonstrate enlargement of the pituitary gland and/or stalk, sometimes with signal alterations of the affected structures, including absence of the expected hyperintense T1 signal in the posterior pituitary gland. Orbital involvement is frequent and includes infiltrating soft-tissue masses with concurrent exophthalmos. Associated osteosclerosis of the maxillofacial bones may be present.¹¹ Spinal involvement is less common and has variable appearances. Some patients have multifocal T2-hyperintense, enhancing intramedullary lesions.¹³ Others have extramedullary masses that may compress or even infiltrate the cord (Fig 4).

FIG 4.

Schematic showing the various types of involvement of ECD in the CNS. Intracranially, the most common findings are focal areas of enhancement in the brainstem and/or cerebellum, with surrounding edema. The pituitary infundibulum is commonly enlarged. In the spine, both intramedullary lesions and extramedullary lesions are observed, which are often associated with adjacent edema.

The imaging findings of CNS ECD are protean and location-dependent; as a result, the differential considerations are highly variable. The patchy brainstem enhancement seen in many patients can mimic CLIPPERS or CNS lymphoma but tends to be more confluent than CLIPPERS and does not respond to steroids like these 2 entities.¹⁴ Supratentorial involvement of white matter lesions, though rare, may raise concern for MS. Dural-based masses can share the appearance of meningiomas, though this is more common in Rosai-Dorfman disease (RDD).^15,16 In the spine, extramedullary masses along nerve roots have been mistaken for schwannomas.¹⁷

Other histiocytic disorders can also involve the CNS. RDD is characterized by histiocyte proliferation that leads to lymphatic sinus dilation. Although patients often present with painless cervical lymphadenopathy, extranodal disease is not uncommon.¹⁸ As stated above, intracranial manifestations of RDD mimic meningiomas: The disease typically presents as dural-based masses, often around the cavernous sinuses and sella region.¹⁹

Langerhans cell histiocytosis (LCH) is characterized by accumulations of epidermal dendritic cells. CNS involvement is relatively rare, usually presenting as a pituitary dysfunction such as diabetes insipidus. On imaging, the most common findings are thickening of the pituitary stalk, an enhancing suprasellar mass, and loss of normal T1 signal in the posterior pituitary gland.¹⁵ Neurodegenerative changes can also be seen, presenting as symmetric signal abnormalities in the dentate nuclei, pons, and basal ganglia, as well as focal or diffuse parenchymal atrophy.²⁰ Patients also commonly have skeletal involvement, with lytic lesions in the skull and vertebra plana in the spine (Table).

View this table:

Demographics and most frequently observed CNS imaging features of ECD, RDD, and LCH

Fortunately, involvement of extra-CNS organs can provide further diagnostic clues. The most common finding is sclerotic osseous lesions symmetrically involving the diaphysis of the long bones. On technetium Tc99m hydroxymethylene diphosphonate bone scans, these will demonstrate strong uptake, particularly in the distal metaphyseal regions of the femur and proximal epiphyseal regions of the tibia (the so-called “hot knees” sign, which is pathognomonic of ECD).^21,22 Perinephric fibrosis related to fat infiltration leads to the appearance of “hairy kidneys,” while retroperitoneal fibrosis can encase the descending aorta (“coated aorta”).^23,24

Histologically, ECD is characterized by infiltrates of foamy, lipid-laden histocytes with small nuclei. Multinucleated Touton giant cells are frequently present. By immunohistochemistry, the neoplastic cells are highlighted by the histiocytic markers CD68 and CD163 but are negative for CD1a and langerin, differentiating ECD from LCH, and are negative or weakly positive for S-100, differentiating ECD from RDD.²⁵ The histologic findings in CNS ECD may be subtle relative to other organ systems, and confirmation of a mitogen-activated protein kinase (MAPK) alteration is often necessary to establish a definitive diagnosis. The mutation-specific BRAF p.V600E antibody can identify cases having this alteration. Identification of other MAPK alterations requires sequencing studies. MAPK alterations are not specific to ECD and may be observed in LCH as well as gliomas and other tumor types. Therefore, diagnosis of ECD requires integration of clinical, histologic, and molecular features.

Current treatment of these disorders relies on identification of pathogenic mutations in the affected tissue and treatment with pathway inhibitors. Patients with CNS involvement invariably require treatment, whereas isolated single-system disease such as pulmonary disease can often be monitored. Vemurafenib, a BRAF inhibitor, was the first FDA-approved therapy for histiocytic disorders for patients with the BRAF p.V600E mutation.²⁶ Cobimetinib is a mitogen-activated ERK kinase (MEK) inhibitor, which was approved in 2022 for treatment of ECD, regardless of mutation status. For patients not responding to these agents who do not have another targetable mutation, cytotoxic therapies such as cladribine or methotrexate are typically used.

The treatment of ECD has evolved with time.²⁷ Surgery, radiation therapy, steroids, cytotoxic drugs, and interferon-α have all been used with variable efficacy.^28,29 Then, multiple studies found that more than one-half of ECD tissue samples demonstrated BRAF p.V600E mutations.^30,31 This discovery led to the use of vemurafenib, a BRAF p.V600E inhibitor, which has shown remarkable efficacy in early reports.^32,33 It was subsequently found that patients lacking BRAF p.V600E mutations often have activating mutations elsewhere in the MAPK pathway.³⁴ This finding led to other treatment options, including MEK and rapidly accelerated fibrosarcoma inhibitors.³⁵ Still, no standardized treatment regimen exists; management is usually based on disease severity, the results of genomic analyses, and clinicians’ preferences.

The prognosis of patients with ECD is highly variable and is predominantly influenced by specific organ involvement. CNS disease tends to respond rapidly to BRAF/MEK inhibition if enhancing lesions are present, though in patients with nonenhancing, presumably chronic lesions, residual deficits are typical. A 2011 study of 53 patients found that the 5-year survival was 68%, though these results were published before recent treatment advances.³⁶ Both increased age and CNS involvement are independent predictors of poor prognoses.^36,37 In patients with BRAF p.V600E–mutated disease, almost all stabilize or respond to therapy if they tolerate the medication.^5,38 Follow-up imaging is typically performed every 3–6 months early on in the treatment course.

After initiation of vemurafenib, this patient had a substantial improvement in gait ataxia within 1 week, going from walking with a walker to no gait aid. At 3-month follow up, he was walking without aid, had returned to work, and had a persistent moderate ataxic dysarthria. MR imaging of the brain at that time demonstrated a reduction in the degree of enhancement within his dentate nuclei.

Case Summary

CNS involvement of ECD is variable. Characteristic findings include patchy T2 hyperintensities and/or enhancement in the brainstem and cerebellum, thickening of the pituitary infundibulum, and dural-based extra-axial masses.
Diabetes insipidus is the most common clinical manifestation of neurologic ECD and can precede the diagnosis by up to a decade. Other neurologic symptoms are dependent on the sites of involvement.
Diagnosis is best made by biopsy, with molecular genetic testing to evaluate causative mutations.
Identification of the biopsy target using vertex-to-toes PET/CT is an essential component of evaluation of these disorders.
Histopathologic findings of CNS ECD can be very subtle relative to other organ systems. In the proper clinical context, molecular testing for BRAF or other MAPK pathway alterations can aid in establishing a definitive diagnosis.
Treatment strategies have evolved during recent years. Targeted therapeutic regimens are now often based on genomic analyses of tissue samples.

Footnotes

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

References

1.↵
1. Sedrak P,
2. Ketonen L,
3. Hou P, et al
. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 2011;32:2126–31 doi:10.3174/ajnr.A2707 pmid:21960492
Abstract/FREE Full Text
2.↵
1. Oliveira M,
2. Monteiro S,
3. Dos Santos J, et al
. Erdheim-Chester disease: a rare clinical entity. Eur J Case Rep Intern Med 2020;7:001630 doi:10.12890/2020_001630 pmid:32908822
CrossRef PubMed
3.↵
1. Todisco A,
2. Cavaliere C,
3. Vaglio A, et al
. Erdheim-Chester disease: a challenging diagnosis for an effective therapy. Clin Neurol Neurosurg 2020;194:105841 doi:10.1016/j.clineuro.2020.105841 pmid:32330799
CrossRef PubMed
4.↵
1. Sánchez-Villalobos JM,
2. Jimeno-Almazán A,
3. López-Peña C, et al
. Erdheim-Chester disease mimicking multiple sclerosis or a new association? Mult Scler Relat Disord 2019;30:94–97 doi:10.1016/j.msard.2019.02.008 pmid:30743087
CrossRef PubMed
5.↵
1. Pegoraro F,
2. Papo M,
3. Maniscalco V, et al
. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia 2020;34:2840–57 doi:10.1038/s41375-020-0944-4 pmid:32591646
CrossRef PubMed
6.↵
1. Cohen Aubart F,
2. Idbaih A,
3. Galanaud D, et al
. Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology 2020;95:e2746–54 doi:10.1212/WNL.0000000000010748 pmid:32887776
CrossRef PubMed
7.↵
1. Garg N,
2. Lavi ES
. Clinical and neuroimaging manifestations of Erdheim-Chester disease: a review. J Neuroimaging 2021;31:35–44 doi:10.1111/jon.12785 pmid:32920940
CrossRef PubMed
8.↵
1. Abdelfattah AM,
2. Arnaout K,
3. Tabbara IA
. Erdheim-Chester disease: a comprehensive review. Anticancer Res 2014;34:3257–61 pmid:24982329
Abstract/FREE Full Text
9.↵
1. Manaka K,
2. Sato J,
3. Makita N
. Neuroendocrine manifestations of Erdheim-Chester disease. Handb Clin Neurol 2021;181:137–47 doi:10.1016/B978-0-12-820683-6.00010-5 pmid:34238453
CrossRef PubMed
10.↵
1. Cives M,
2. Simone V,
3. Rizzo FM, et al
. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol 2015;95:1–11 doi:10.1016/j.critrevonc.2015.02.004 pmid:25744785
CrossRef PubMed
11.↵
1. Kumar P,
2. Singh A,
3. Gamanagatti S, et al
. Imaging findings in Erdheim-Chester disease: what every radiologist needs to know. Pol J Radiol 2018;83:e54–62 doi:10.5114/pjr.2018.73290 pmid:30038679
CrossRef PubMed
12.↵
1. Caparros-Lefebvre D,
2. Pruvo JP,
3. Rémy M, et al
. Neuroradiologic aspects of Chester-Erdheim disease. AJNR Am J Neuroradiol 1995;16:735–40 pmid:7611030
Abstract/FREE Full Text
13.↵
1. Jeon I,
2. Choi JH
. Isolated thoracic intramedullary Erdheim-Chester disease presenting with paraplegia: a case report and literature review. BMC Musculoskelet Disord 2021;22:270 doi:10.1186/s12891-021-04061-7 pmid:33711983
CrossRef PubMed
14.↵
1. Berkman J,
2. Ford C,
3. Johnson E, et al
. Misdiagnosis: CNS Erdheim–Chester disease mimicking CLIPPERS. Neuroradiol J 2018;31:399–402 doi:10.1177/1971400917710251 pmid:28685649
CrossRef PubMed
15.↵
1. Wang Y,
2. Camelo-Piragua S,
3. Abdullah A, et al
. Neuroimaging features of CNS histiocytosis syndromes. Clin Imaging 2020;60:131–40 doi:10.1016/j.clinimag.2019.10.001 pmid:31874337
CrossRef PubMed
16.↵
1. Johnson MD,
2. Aulino JP,
3. Jagasia M, et al
. Erdheim-Chester disease mimicking multiple meningiomas syndrome. AJNR Am J Neuroradiol 2004;25:134–37 pmid:14729543
Abstract/FREE Full Text
17.↵
1. Huang Z,
2. Li S,
3. Hong J, et al
. Erdheim-Chester disease mimicking lumbar nerve schwannoma: case report and literature review. Spinal Cord Ser Cases 2019;5:90 doi:10.1038/s41394-019-0234-4 pmid:31700688
CrossRef PubMed
18.↵
1. Unadkat BS,
2. Kashikar SV,
3. Bhansali PJ, et al
. Intracranial Rosai-Dorfman disease: a case to remember. Cureus 2022;14:e32605 doi:10.7759/cureus.32605 pmid:36660540
CrossRef PubMed
19.↵
1. Cheng X,
2. Cheng JL,
3. Gao AK
. A study on clinical characteristics and magnetic resonance imaging manifestations on systemic Rosai-Dorfman disease. Chin Med J (Engl) 2018;131:440–47 doi:10.4103/0366-6999.225053 pmid:29451149
CrossRef PubMed
20.↵
1. Prosch H,
2. Grois N,
3. Wnorowski M, et al
. Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2007;28:1022–28 doi:10.3174/ajnr.A0509 pmid:17569949
CrossRef PubMed
21.↵
1. Cerudelli E,
2. Gazzilli M,
3. Bertoli M, et al
. Erdheim-Chester disease: the power of nuclear medicine imaging. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020;39:323–24 doi:10.1016/j.remn.2020.01.003 pmid:32616456
CrossRef PubMed
22.↵
1. Fasulo S,
2. Alkomos MF,
3. Pjetergjoka R, et al
. Erdheim-Chester disease presenting at the central nervous system. Autops Case Rep 2021;11:e2021321 doi:10.4322/acr.2021.321 pmid:34540726
CrossRef PubMed
23.↵
1. Liu SZ,
2. Zhou X,
3. Song A, et al
. Exophthalmos and coated aorta in Erdheim–Chester disease. Rheumatology (Oxford) 2020;59:2651–52 doi:10.1093/rheumatology/keaa022 pmid:32025736
CrossRef PubMed
24.↵
1. Hazim AZ,
2. Acosta-Medina AA,
3. Young JR, et al
; Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Classical and non-classical phenotypes of Erdheim-Chester disease: correlating clinical, radiographic and genotypic findings. Br J Haematol 2022;199:454–57 doi:10.1111/bjh.18422 pmid:36017680
CrossRef PubMed
25.↵
1. Emile JF,
2. Tirabosco R
, Demicco, Elizabeth. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. Vol 6. 5th ed. 2021
26.↵
1. Go RS,
2. Jacobsen E,
3. Baiocchi R, et al
. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:1277–303 doi:10.6004/jnccn.2021.0053 pmid:34781268
CrossRef PubMed
27.↵
1. Munoz J,
2. Janku F,
3. Cohen PR, et al
. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc 2014;89:985–96 doi:10.1016/j.mayocp.2014.01.023 pmid:24814521
CrossRef PubMed
28.↵
1. Pan Z,
2. Kleinschmidt-DeMasters BK
. CNS Erdheim-Chester disease: a challenge to diagnose. J Neuropathol Exp Neurol 2017;76:986–96 doi:10.1093/jnen/nlx095 pmid:29096034
CrossRef PubMed
29.↵
1. Haque A,
2. Pérez CA,
3. Reddy TA, et al
. Erdheim-Chester disease with isolated CNS involvement: a systematic review of the literature. Neurol Int 2022;14:716–26 doi:10.3390/neurolint14030060 pmid:36135995
CrossRef PubMed
30.↵
1. Badalian-Very G
. A common progenitor cell in LCH and ECD. Blood 2014;124:991–92 doi:10.1182/blood-2014-06-581736 pmid:25124781
FREE Full Text
31.↵
1. Haroche J,
2. Charlotte F,
3. Arnaud L, et al
. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosis. Blood 2012;120:2700–03 doi:10.1182/blood-2012-05-430140 pmid:22879539
Abstract/FREE Full Text
32.↵
1. Tzoulis C,
2. Schwarzlmüller T,
3. Gjerde IO, et al
. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes 2015;8:171 doi:10.1186/s13104-015-1135-7 pmid:25926131
CrossRef PubMed
33.↵
1. Costa S,
2. Julião MJ,
3. Silva S, et al
. Erdheim-Chester disease: a rare non-Langerhans histiocytosis. BMJ Case Rep 2021;14:e24114 doi:10.1136/bcr-2020-241143 pmid:34588200
CrossRef PubMed
34.↵
1. Starkebaum G,
2. Hendrie P
. Erdheim-Chester disease. Best Pract Res Clin Rheumatol 2020;34:101510 doi:10.1016/j.berh.2020.101510 pmid:32305313
CrossRef PubMed
35.↵
1. Diamond EL,
2. Durham BH,
3. Haroche J, et al
. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6:154–65 doi:10.1158/2159-8290.CD-15-0913 pmid:26566875
Abstract/FREE Full Text
36.↵
1. Arnaud L,
2. Hervier B,
3. Néel A, et al
. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778–82 doi:10.1182/blood-2010-06-294108 pmid:21239701
Abstract/FREE Full Text
37.↵
1. Veyssier-Belot C,
2. Cacoub P,
3. Caparros-Lefebvre D, et al
. Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996;75:157–69 doi:10.1097/00005792-199605000-00005 pmid:8965684
CrossRef PubMed
38.↵
1. Diamond EL,
2. Subbiah V,
3. Lockhart AC, et al
. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol 2018;4:384–88 doi:10.1001/jamaoncol.2017.5029 pmid:29188284
CrossRef PubMed

Received January 12, 2023.
Accepted after revision February 23, 2023.

In this issue

Download PDF

Email Article

Citation Tools

Purchase

Cited By...

More in this TOC Section

Show more ADULT BRAIN

[1] 1.↵
Sedrak P,
Ketonen L,
Hou P, et al
. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 2011;32:2126–31 doi:10.3174/ajnr.A2707 pmid:21960492
Abstract/FREE Full Text

[2] Sedrak P,

[3] Ketonen L,

[4] Hou P, et al

[5] 2.↵
Oliveira M,
Monteiro S,
Dos Santos J, et al
. Erdheim-Chester disease: a rare clinical entity. Eur J Case Rep Intern Med 2020;7:001630 doi:10.12890/2020_001630 pmid:32908822
CrossRef PubMed

[6] Oliveira M,

[7] Monteiro S,

[8] Dos Santos J, et al

[9] 3.↵
Todisco A,
Cavaliere C,
Vaglio A, et al
. Erdheim-Chester disease: a challenging diagnosis for an effective therapy. Clin Neurol Neurosurg 2020;194:105841 doi:10.1016/j.clineuro.2020.105841 pmid:32330799
CrossRef PubMed

[10] Todisco A,

[11] Cavaliere C,

[12] Vaglio A, et al

[13] 4.↵
Sánchez-Villalobos JM,
Jimeno-Almazán A,
López-Peña C, et al
. Erdheim-Chester disease mimicking multiple sclerosis or a new association? Mult Scler Relat Disord 2019;30:94–97 doi:10.1016/j.msard.2019.02.008 pmid:30743087
CrossRef PubMed

[14] Sánchez-Villalobos JM,

[15] Jimeno-Almazán A,

[16] López-Peña C, et al

[17] 5.↵
Pegoraro F,
Papo M,
Maniscalco V, et al
. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia 2020;34:2840–57 doi:10.1038/s41375-020-0944-4 pmid:32591646
CrossRef PubMed

[18] Pegoraro F,

[19] Papo M,

[20] Maniscalco V, et al

[21] 6.↵
Cohen Aubart F,
Idbaih A,
Galanaud D, et al
. Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology 2020;95:e2746–54 doi:10.1212/WNL.0000000000010748 pmid:32887776
CrossRef PubMed

[22] Cohen Aubart F,

[23] Idbaih A,

[24] Galanaud D, et al

[25] 7.↵
Garg N,
Lavi ES
. Clinical and neuroimaging manifestations of Erdheim-Chester disease: a review. J Neuroimaging 2021;31:35–44 doi:10.1111/jon.12785 pmid:32920940
CrossRef PubMed

[26] Garg N,

[27] Lavi ES

[28] 8.↵
Abdelfattah AM,
Arnaout K,
Tabbara IA
. Erdheim-Chester disease: a comprehensive review. Anticancer Res 2014;34:3257–61 pmid:24982329
Abstract/FREE Full Text

[29] Abdelfattah AM,

[30] Arnaout K,

[31] Tabbara IA

[32] 9.↵
Manaka K,
Sato J,
Makita N
. Neuroendocrine manifestations of Erdheim-Chester disease. Handb Clin Neurol 2021;181:137–47 doi:10.1016/B978-0-12-820683-6.00010-5 pmid:34238453
CrossRef PubMed

[33] Manaka K,

[34] Sato J,

[35] Makita N

[36] 10.↵
Cives M,
Simone V,
Rizzo FM, et al
. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol 2015;95:1–11 doi:10.1016/j.critrevonc.2015.02.004 pmid:25744785
CrossRef PubMed

[37] Cives M,

[38] Simone V,

[39] Rizzo FM, et al

[40] 11.↵
Kumar P,
Singh A,
Gamanagatti S, et al
. Imaging findings in Erdheim-Chester disease: what every radiologist needs to know. Pol J Radiol 2018;83:e54–62 doi:10.5114/pjr.2018.73290 pmid:30038679
CrossRef PubMed

[41] Kumar P,

[42] Singh A,

[43] Gamanagatti S, et al

[44] 12.↵
Caparros-Lefebvre D,
Pruvo JP,
Rémy M, et al
. Neuroradiologic aspects of Chester-Erdheim disease. AJNR Am J Neuroradiol 1995;16:735–40 pmid:7611030
Abstract/FREE Full Text

[45] Caparros-Lefebvre D,

[46] Pruvo JP,

[47] Rémy M, et al

[48] 13.↵
Jeon I,
Choi JH
. Isolated thoracic intramedullary Erdheim-Chester disease presenting with paraplegia: a case report and literature review. BMC Musculoskelet Disord 2021;22:270 doi:10.1186/s12891-021-04061-7 pmid:33711983
CrossRef PubMed

[49] Jeon I,

[50] Choi JH

[51] 14.↵
Berkman J,
Ford C,
Johnson E, et al
. Misdiagnosis: CNS Erdheim–Chester disease mimicking CLIPPERS. Neuroradiol J 2018;31:399–402 doi:10.1177/1971400917710251 pmid:28685649
CrossRef PubMed

[52] Berkman J,

[53] Ford C,

[54] Johnson E, et al

[55] 15.↵
Wang Y,
Camelo-Piragua S,
Abdullah A, et al
. Neuroimaging features of CNS histiocytosis syndromes. Clin Imaging 2020;60:131–40 doi:10.1016/j.clinimag.2019.10.001 pmid:31874337
CrossRef PubMed

[56] Wang Y,

[57] Camelo-Piragua S,

[58] Abdullah A, et al

[59] 16.↵
Johnson MD,
Aulino JP,
Jagasia M, et al
. Erdheim-Chester disease mimicking multiple meningiomas syndrome. AJNR Am J Neuroradiol 2004;25:134–37 pmid:14729543
Abstract/FREE Full Text

[60] Johnson MD,

[61] Aulino JP,

[62] Jagasia M, et al

[63] 17.↵
Huang Z,
Li S,
Hong J, et al
. Erdheim-Chester disease mimicking lumbar nerve schwannoma: case report and literature review. Spinal Cord Ser Cases 2019;5:90 doi:10.1038/s41394-019-0234-4 pmid:31700688
CrossRef PubMed

[64] Huang Z,

[65] Li S,

[66] Hong J, et al

[67] 18.↵
Unadkat BS,
Kashikar SV,
Bhansali PJ, et al
. Intracranial Rosai-Dorfman disease: a case to remember. Cureus 2022;14:e32605 doi:10.7759/cureus.32605 pmid:36660540
CrossRef PubMed

[68] Unadkat BS,

[69] Kashikar SV,

[70] Bhansali PJ, et al

[71] 19.↵
Cheng X,
Cheng JL,
Gao AK
. A study on clinical characteristics and magnetic resonance imaging manifestations on systemic Rosai-Dorfman disease. Chin Med J (Engl) 2018;131:440–47 doi:10.4103/0366-6999.225053 pmid:29451149
CrossRef PubMed

[72] Cheng X,

[73] Cheng JL,

[74] Gao AK

[75] 20.↵
Prosch H,
Grois N,
Wnorowski M, et al
. Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2007;28:1022–28 doi:10.3174/ajnr.A0509 pmid:17569949
CrossRef PubMed

[76] Prosch H,

[77] Grois N,

[78] Wnorowski M, et al

[79] 21.↵
Cerudelli E,
Gazzilli M,
Bertoli M, et al
. Erdheim-Chester disease: the power of nuclear medicine imaging. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020;39:323–24 doi:10.1016/j.remn.2020.01.003 pmid:32616456
CrossRef PubMed

[80] Cerudelli E,

[81] Gazzilli M,

[82] Bertoli M, et al

[83] 22.↵
Fasulo S,
Alkomos MF,
Pjetergjoka R, et al
. Erdheim-Chester disease presenting at the central nervous system. Autops Case Rep 2021;11:e2021321 doi:10.4322/acr.2021.321 pmid:34540726
CrossRef PubMed

[84] Fasulo S,

[85] Alkomos MF,

[86] Pjetergjoka R, et al

[87] 23.↵
Liu SZ,
Zhou X,
Song A, et al
. Exophthalmos and coated aorta in Erdheim–Chester disease. Rheumatology (Oxford) 2020;59:2651–52 doi:10.1093/rheumatology/keaa022 pmid:32025736
CrossRef PubMed

[88] Liu SZ,

[89] Zhou X,

[90] Song A, et al

[91] 24.↵
Hazim AZ,
Acosta-Medina AA,
Young JR, et al
; Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Classical and non-classical phenotypes of Erdheim-Chester disease: correlating clinical, radiographic and genotypic findings. Br J Haematol 2022;199:454–57 doi:10.1111/bjh.18422 pmid:36017680
CrossRef PubMed

[92] Hazim AZ,

[93] Acosta-Medina AA,

[94] Young JR, et al

[95] 25.↵
Emile JF,
Tirabosco R
, Demicco, Elizabeth. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. Vol 6. 5th ed. 2021

[96] Emile JF,

[97] Tirabosco R

[98] 26.↵
Go RS,
Jacobsen E,
Baiocchi R, et al
. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:1277–303 doi:10.6004/jnccn.2021.0053 pmid:34781268
CrossRef PubMed

[99] Go RS,

[100] Jacobsen E,

[101] Baiocchi R, et al

[102] 27.↵
Munoz J,
Janku F,
Cohen PR, et al
. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc 2014;89:985–96 doi:10.1016/j.mayocp.2014.01.023 pmid:24814521
CrossRef PubMed

[103] Munoz J,

[104] Janku F,

[105] Cohen PR, et al

[106] 28.↵
Pan Z,
Kleinschmidt-DeMasters BK
. CNS Erdheim-Chester disease: a challenge to diagnose. J Neuropathol Exp Neurol 2017;76:986–96 doi:10.1093/jnen/nlx095 pmid:29096034
CrossRef PubMed

[107] Pan Z,

[108] Kleinschmidt-DeMasters BK

[109] 29.↵
Haque A,
Pérez CA,
Reddy TA, et al
. Erdheim-Chester disease with isolated CNS involvement: a systematic review of the literature. Neurol Int 2022;14:716–26 doi:10.3390/neurolint14030060 pmid:36135995
CrossRef PubMed

[110] Haque A,

[111] Pérez CA,

[112] Reddy TA, et al

[113] 30.↵
Badalian-Very G
. A common progenitor cell in LCH and ECD. Blood 2014;124:991–92 doi:10.1182/blood-2014-06-581736 pmid:25124781
FREE Full Text

[114] Badalian-Very G

[115] 31.↵
Haroche J,
Charlotte F,
Arnaud L, et al
. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosis. Blood 2012;120:2700–03 doi:10.1182/blood-2012-05-430140 pmid:22879539
Abstract/FREE Full Text

[116] Haroche J,

[117] Charlotte F,

[118] Arnaud L, et al

[119] 32.↵
Tzoulis C,
Schwarzlmüller T,
Gjerde IO, et al
. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes 2015;8:171 doi:10.1186/s13104-015-1135-7 pmid:25926131
CrossRef PubMed

[120] Tzoulis C,

[121] Schwarzlmüller T,

[122] Gjerde IO, et al

[123] 33.↵
Costa S,
Julião MJ,
Silva S, et al
. Erdheim-Chester disease: a rare non-Langerhans histiocytosis. BMJ Case Rep 2021;14:e24114 doi:10.1136/bcr-2020-241143 pmid:34588200
CrossRef PubMed

[124] Costa S,

[125] Julião MJ,

[126] Silva S, et al

[127] 34.↵
Starkebaum G,
Hendrie P
. Erdheim-Chester disease. Best Pract Res Clin Rheumatol 2020;34:101510 doi:10.1016/j.berh.2020.101510 pmid:32305313
CrossRef PubMed

[128] Starkebaum G,

[129] Hendrie P

[130] 35.↵
Diamond EL,
Durham BH,
Haroche J, et al
. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6:154–65 doi:10.1158/2159-8290.CD-15-0913 pmid:26566875
Abstract/FREE Full Text

[131] Diamond EL,

[132] Durham BH,

[133] Haroche J, et al

[134] 36.↵
Arnaud L,
Hervier B,
Néel A, et al
. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778–82 doi:10.1182/blood-2010-06-294108 pmid:21239701
Abstract/FREE Full Text

[135] Arnaud L,

[136] Hervier B,

[137] Néel A, et al

[138] 37.↵
Veyssier-Belot C,
Cacoub P,
Caparros-Lefebvre D, et al
. Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996;75:157–69 doi:10.1097/00005792-199605000-00005 pmid:8965684
CrossRef PubMed

[139] Veyssier-Belot C,

[140] Cacoub P,

[141] Caparros-Lefebvre D, et al

[142] 38.↵
Diamond EL,
Subbiah V,
Lockhart AC, et al
. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol 2018;4:384–88 doi:10.1001/jamaoncol.2017.5029 pmid:29188284
CrossRef PubMed

[143] Diamond EL,

[144] Subbiah V,

[145] Lockhart AC, et al

Main menu

User menu

Search

American Journal of Neuroradiology

Erdheim-Chester Disease

Abstract

ABBREVIATIONS:

Imaging

Operative Report

Pathology

DISCUSSION

Case Summary

Footnotes

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology

Main menu

User menu

Search

Erdheim-Chester Disease

Abstract

ABBREVIATIONS:

Imaging

Operative Report

Pathology

DISCUSSION

Case Summary

Footnotes

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology